AMBP and cholangiocarcinoma: Accordingly, four significant proteins from our proteomic analysis, S100A9, AACT, AFM, and TAOK3, and three potential CCA biomarkers from previous studies, NGAL, PSMA3, and AMBP, were selected for further validation using the clinically compatible antibody-based assay.